title: [Protective effects of perfluorocarbon combined with ligustrazine against lung ischemia-reperfusion injury in rats].
abstract: OBJECTIVE
  To investigate the effects of perfluorocarbon and ligustrazine in protecting the lungs against ischemia-reperfusion injury in rats.
  
  
  METHODS
  Forty SD rats with ischemia-reperfusion lung injury were randomized equally into control, ligustrazine, perfluorocarbon, and perfluorocarbon plus ligustrazine groups and received the corresponding treatment via the tail vein 5 min before reperfusion. The lung tissues were harvested and the levels of malondialdehyde (MDA), myeloperoxidase (MPO), superoxide dismutase (SOD) and tumor necrosis factor-α (TNF-α) were detected 3 h after reperfusion. The pathological changes and pathological scores of the lung tissues were analyzed.
  
  
  RESULTS
  MDA and MPO levels were significantly lower and SOD activities significantly higher in the lung tissues in the 3 treatment groups than in the control group (P<0.05). The rats in the combined treatment group showed a significantly lower MPO level and a significantly higher SOD activity than those treated with ligustrazine or perfluorocarbon alone (P<0.05). No significant difference was found in TNF-α levels in the lung tissues among the 4 groups (P>0.05). The lung tissues in the control group showed obvious edema and exudation, and the tissues in ligustrazine and perfluorocarbon groups showed no edema but with a few red blood cells and exudation; no edema was found in the combined treatment group with only a small amount of exudation. The pathological scores differed significantly among the 4 groups.
  
  
  CONCLUSIONS
  Perfluorocarbon and ligustrazine, especially in combined use, can promote endogenous oxygen free radical scavenging, decrease peripheral blood proinflammatory cytokines, and inhibit neutrophils filtration in the lungs of rats with ischemia/reperfusion lung injury.
authors.affiliation: Department of Anesthesiology, First Affiliated Hospital of Jinan University, Guangzhou 510630, China. E-mail: zzx415@163.com.
authors.forename: Zhi-Xiong
authors.initials: ZX
authors.lastname: Zheng
authors.forename: Xue-Mei
authors.initials: XM
authors.lastname: Peng
authors.forename: Lu
authors.initials: L
authors.lastname: Xi
authors.forename: Dong-Hua
authors.initials: DH
authors.lastname: Hu
authors.forename: Chun-Ying
authors.initials: CY
authors.lastname: Lu
mesh_terms: D000818:Animals; D016207:Cytokines; D005466:Fluorocarbons / Q000494:pharmacology*; D055370:Lung Injury / Q000188:drug therapy*; D008315:Malondialdehyde / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D020011:Protective Agents / Q000494:pharmacology*; D011719:Pyrazines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000188:drug therapy*; D013482:Superoxide Dismutase / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D016207:Cytokines; D005466:Fluorocarbons; D020011:Protective Agents; D011719:Pyrazines; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D009195:Peroxidase; D013482:Superoxide Dismutase; C017953:tetramethylpyrazine